Ticagrelor Tablet, Film Coated
Product Images NDC 42658-115

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 42658-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hisun Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Hisun Ticagrelor 01)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg and Clopidogrel over 360 days from the first study drug dose. The y-axis shows cumulative percentage events, increasing for both drugs, with Ticagrelor having higher cumulative incidence than Clopidogrel throughout. Patient numbers at risk are displayed at multiple time points below the x-axis.*

FDA Label Image

Figure 2 (Hisun Ticagrelor 02)

A bar chart displaying the percentage of patients who had an event following coronary artery bypass grafting (CABG) over a range of days. The x-axis shows days post-CABG (1 through 7 and 8 or more), and the y-axis indicates the percentage of patients. Two groups are compared with bars labeled 'T' and 'C' across each day, with associated patient count data below the x-axis for each group and day.*

FDA Label Image

Chemical Structure (Hisun Ticagrelor 03)

Chemical structure of ticagrelor, showing its molecular components and bonds, including a fluorinated phenyl group and a thienopyrimidine core.*

FDA Label Image

Figure 3 (Hisun Ticagrelor 04)

A line graph showing IPA (%) induced by 20 µM ADP over time (hours) comparing three groups: Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. The graph plots IPA percentage on the vertical axis and time in hours on the horizontal axis, depicting higher IPA values for Ticagrelor throughout the 8-hour period.*

FDA Label Image

Figure 4 (Hisun Ticagrelor 05)

A line graph comparing IPA (%) induced by 20μM ADP over time (days) for Ticagrelor, Clopidogrel, and Placebo. The graph shows measurements from day 0 to day 10, with Ticagrelor and Clopidogrel showing higher IPA levels than Placebo. An inset graph plots the same variables over hours (0 to 48), illustrating an early time course of IPA response.*

FDA Label Image

Figure 6 (Hisun Ticagrelor 07)

A pharmacokinetic chart showing the mean effect and 90% confidence interval of Ticagrelor and AR-C124910XX with various interacting drugs. The x-axis indicates change relative to reference, measuring parameters Cmax and AUC. Recommendations on drug interactions include avoiding concomitant use or no dose adjustment for specific drugs listed.*

FDA Label Image

Figure 7 (Hisun Ticagrelor 08)

A chart showing the effect of various interacting drugs on Ticagrelor dose, with mean effect and 90% confidence intervals plotted as Cmax and AUC values. The chart lists drugs including Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine, alongside dosing recommendations such as maximum Simvastatin dose or no dose adjustment required.*

FDA Label Image

Figure 8 (Hisun Ticagrelor 09)

A line graph showing cumulative percentage over 360 days from randomization comparing Ticagrelor 90 mg and Clopidogrel in patients. The graph includes data on numbers at risk and statistical values such as events, Kaplan-Meier percentage at 12 months, hazard ratio with confidence interval, and p-value, illustrating a comparative analysis of patient events between the two treatments.*

FDA Label Image

Figure 9 (Hisun Ticagrelor 10)

A forest plot comparing the hazard ratios and 95% confidence intervals for Ticagrelor versus Clopidogrel across various patient characteristics and treatment effects. The plot includes subgroups such as geographic location, ASA dose, treatment approach, diabetes history, prior stroke, age, sex, and race, illustrating comparative effectiveness with Ticagrelor favored on the left and Clopidogrel favored on the right.*

FDA Label Image

Figure 10 (Hisun Ticagrelor 11)

A data table comparing outcomes with Ticagrelor and Clopidogrel by region (US and Non-US) and aspirin dose categories. It presents the number of events and participants for each drug, along with hazard ratios and confidence intervals, accompanied by a forest plot showing relative effectiveness between Ticagrelor and Clopidogrel.*

FDA Label Image

Figure 11 (Hisun Ticagrelor 12)

A Kaplan-Meier cumulative incidence graph showing event percentages over time (days from randomization) for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The chart includes patient numbers, events, Kaplan-Meier percentages at 36 months, hazard ratios with confidence intervals, and p-values for comparison between groups.*

FDA Label Image

Figure 12 (Hisun Ticagrelor 13)

A forest plot chart comparing ticagrelor to placebo across various patient subgroups, showing hazard ratios (HR) and 95% confidence intervals (CI) for overall treatment effect and multiple demographic and clinical characteristics. The plot indicates Ticagrelor's effect on reducing events relative to placebo, with subgroup categories on the y-axis and HR values on the x-axis.*

FDA Label Image

Ticagrelor Tablets 90 mg 60 Count Bottle Label (Hisun Ticagrelor 14)

Label for Ticagrelor Tablets 90 mg, a human prescription oral film-coated tablet produced by Hisun Pharmaceuticals USA, Inc. The label indicates a package size of 500 tablets and includes storage instructions, a warning to keep out of reach of children, a barcode, NDC 42658-115, and a note to dispense the accompanying medication guide to patients.*

FDA Label Image

15 (Hisun Ticagrelor 15)

A line graph depicting cumulative percentage of events over 54 months from randomization for Ticagrelor versus Placebo. The solid line represents Ticagrelor with a higher cumulative percentage of events compared to the dashed line for Placebo. The graph includes a legend and a table showing the number of subjects at risk at various time points.*

FDA Label Image

16 (Hisun Ticagrelor 16)

A cumulative percentage line graph comparing Ticagrelor 90 mg twice daily (solid line) versus placebo (dashed line) over days from randomization up to about 34 days. The graph includes event counts, total subjects, and Kaplan-Meier percentages for each group and a table of numbers at risk below the X-axis.*

FDA Label Image

17 (Hisun Ticagrelor 17)

A cumulative percentage line graph comparing Ticagrelor and placebo over months from randomization (0 to 54 months). The y-axis shows cumulative percentage (0% to 14%), with Ticagrelor represented by a solid line and placebo by a dashed line. The graph includes numbers at risk below the x-axis for both groups over time.*

FDA Label Image

18 (Hisun Ticagrelor 18)

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals for various patient subgroups treated with Ticagrelor versus placebo. The chart displays treatment effects across characteristics such as age, sex, race, body mass index, geographic region, baseline aspirin dose, HbA1c, eGFR, insulin use, angina history, coronary disease status, PCI history, time since PCI, CABG history, current smoking status, and diabetes duration. Squares represent HR point estimates with horizontal lines indicating confidence intervals, centered around a vertical line at HR=1.*

FDA Label Image

19 (Hisun Ticagrelor 19)

A cumulative incidence plot comparing Ticagrelor 90 mg twice daily with placebo over 34 days from randomization. The y-axis shows cumulative percentage, while the x-axis shows days. Two lines represent the Ticagrelor group and placebo group event rates, with corresponding at-risk patient counts below the x-axis.*

FDA Label Image

20 (Hisun Ticagrelor 20)

A forest plot chart comparing Ticagrelor and placebo across various patient characteristics and subgroups. The chart shows hazard ratios (HR) with 95% confidence intervals, percentage event rates for Ticagrelor and placebo, and markers indicating treatment effect direction and magnitude for factors like age, sex, race, weight, BMI, geographic region, disease history, and smoking status.*

FDA Label Image

21 (Hisun Ticagrelor 21)

A forest plot chart titled 'Mean effect and 90% CI' showing pharmacokinetic comparisons of Ticagrelor and AR-C124910XX across intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment. The chart depicts changes relative to reference values on the x-axis with markers for Cmax and AUC, indicating no dose adjustment recommendations across all factors.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.